Testosterone treatment of HSDD in naturally menopausal women: the ADORE study

Panay, Nick; Al‐Azzawi, Farook; Bouchard, Céline; Davis, Susan Ruth; Eden, John; Lodhi, Imran; Rees, Margaret; Rodenberg, Cynthia; Rymer, Janice; Schwenkhagen, A.; Sturdee, David W.

doi:10.3109/13697131003675922

Cited by 146 publications

(67 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, the ADORE study, 272 postmenopausal women, the majority of whom were not receiving hormone replacement, were randomized to transdermal testosterone 300 μg daily or placebo for 6 months. The group receiving testosterone reported increased satisfying sexual episodes, improvements in sexual desire, and reduction of distress compared with placebo at the study end point [40]. A group of surgically postmenopausal women with a diagnosis of HSDD were given either 150, 300, or 450 μg daily transdermal testosterone for 24 weeks in addition to estradiol replacement, and the women receiving the two higher doses of testosterone had improvement in sexual desire and frequency of sexual activity compared with the placebo group [41].…”

Section: Interventions For Treatment-emergent Sexual Dysfunction Withmentioning

confidence: 95%

Sexual Function Across Aging

Clayton

Harsh

2016

Curr Psychiatry Rep

View full text Add to dashboard Cite

Women experience multiple changes in social and reproductive statuses across the life span which can affect sexual functioning. Various phases of the sexual response cycle may be impacted and can lead to sexual dysfunction. Screening for sexual problems and consideration of contributing factors such as neurobiology, reproductive life events, medical problems, medication use, and depression can help guide appropriate treatment and thereby improve the sexual functioning and quality of life of affected women. Treatment options include psychotropic medications, hormone therapy, and psychotherapy.

show abstract

Section: Interventions For Treatment-emergent Sexual Dysfunction Withmentioning

confidence: 95%

Sexual Function Across Aging

Clayton

Harsh

2016

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…We analyzed the ten studies included in the Alexander et al (2004) review, focusing specifically on circulating hormone levels produced by treatment and their relationship to sexual desire. In addition, we analyzed five studies excluded from Alexander et al (2004) because they were not double-blind randomized controlled trials (Burger et al, 1987; Davis et al, 1995; Dow et al, 1983; Sarrel et al, 1998; Sherwin & Gelfand, 1987), and eight double-blind randomized controlled trials published after 2004 that investigated the effects of estrogen and/or androgen therapies on sexual desire in postmenopausal women (Braunstein et al, 2005; Buster et al, 2005; Davis et al 2006a, 2006b; 2008; Panay et al, 2010; Shifren et al, 2006; Simon et al, 2005). Table 1 provides details of all studies included in the following review.…”

Section: Hormone Therapies For Low Libido In Postmenopausal Womenmentioning

confidence: 99%

“…Ten double-blind randomized controlled trials have compared the effectiveness of an estrogen therapy alone and in combination with testosterone at increasing sexual desire in postmenopausal women (Braunstein et al, 2005; Buster et al, 2005; Davis et al, 2006b; Floter et al, 2002; Lobo et al, 2003; Panay et al, 2010; Sarrel et al, 1998; Shifren et al, 2000; 2006; Simon et al, 2005). Sarrel et al (1998) administered an esterified estrogen (EE) therapy by itself or in combination with methyltestosterone to postmenopausal women, and reported that neither treatment increased sexual desire as compared to baseline.…”

Section: Hormone Therapies For Low Libido In Postmenopausal Womenmentioning

confidence: 99%

Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens

Cappelletti

Wallen

2016

Hormones and Behavior

138

View full text Add to dashboard Cite

Both estradiol and testosterone have been implicated as the steroid critical for modulating women’s sexual desire. By contrast, in all other female mammals only estradiol has been shown to be critical for female sexual motivation and behavior. Pharmaceutical companies have invested heavily in the development of androgen therapies for female sexual desire disorders, but today there are still no FDA approved androgen therapies for women. Nonetheless, testosterone is currently, and frequently, prescribed off-label for the treatment of low sexual desire in women, and the idea of testosterone as a cure-all for female sexual dysfunction remains popular. This paper places the ongoing debate concerning the hormonal modulation of women’s sexual desire within a historical context, and reviews controlled trials of estrogen and/or androgen therapies for low sexual desire in postmenopausal women. These studies demonstrate that estrogen-only therapies that produce periovulatory levels of circulating estradiol increase sexual desire in postmenopausal women. Testosterone at supraphysiological, but not at physiological, levels enhances the effectiveness of low-dose estrogen therapies at increasing women’s sexual desire; however, the mechanism by which supraphysiological testosterone increases women’s sexual desire in combination with an estrogen remains unknown. Because effective therapies require supraphysiological amounts of testosterone, it remains unclear whether endogenous testosterone contributes to the modulation of women’s sexual desire. The likelihood that an androgen-only clinical treatment will meaningfully increase women’s sexual desire is minimal, and the focus of pharmaceutical companies on the development of androgen therapies for the treatment of female sexual desire disorders is likely misplaced.

show abstract

“…These women are also candidates for testosterone therapy. [53][54][55] There are currently no female testosterone therapies registered or available in South Africa (SA). Tibolone, which has weak androgenic, oestrogenic and progestogenic activity and does not increase sex hormone binding globulin, can be used as an alternative to testosterone.…”

Section: Androgen Therapymentioning

confidence: 99%

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Guidozzi

Alperstein²,

Bagratee

et al. 2014

S Afr Med J

View full text Add to dashboard Cite

The South African Menopause Society (SAMS) consensus position statement on menopausal hormone therapy (HT) 2014 is a revision of the SAMS Council consensus statement on menopausal HT published in the SAMJ in May 2007. Information presented in the previous statement has been re-evaluated and new evidence has been incorporated. While the recommendations pertaining to HT remain similar to those in the previous statement, the 2014 revision includes a wider range of clinical benefits for HT, the inclusion of non-hormonal alternatives such as selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors for the management of vasomotor symptoms, and an appraisal of bioidentical hormones and complementary medicines used for treatment of menopausal symptoms. New preparations that are likely to be more commonly used in the future are also mentioned. The revised statement emphasises that commencing HT during the 'therapeutic window of opportunity' maximises the benefit-to-risk profile of therapy in symptomatic menopausal women.

show abstract

Testosterone treatment of HSDD in naturally menopausal women: the ADORE study

Abstract: TTP was effective in treating HSDD and improving sexual function in this study of naturally menopausal women with and without concurrent hormone therapy.

Cited by 146 publications

References 22 publications

Sexual Function Across Aging

Sexual Function Across Aging

Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Contact Info

Product

Resources

About